Evidence map›Paper›PMID 38519798›Full record

ArticleLeukemia2024

The Eμ-Ret mouse is a novel model of hyperdiploid B-cell acute lymphoblastic leukemia.

Ali Farrokhi, Tanmaya Atre, Jenna Rever, Mario Fidanza, Wendy Duey, Samuel Salitra, Junia Myung, Meiyun Guo, Sumin Jo, Anuli Uzozie and 10 more

Open access · hybridAbstract read
In one paragraph

Article in Leukemia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. CD4Cancer medicine · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 3 countries.

Ali Farrokhi *Michael Cuccione Childhood Cancer Research Program, BC Children's Hospital Research Institute, Vancouver, BC, Canada.
Tanmaya Atre *Michael Cuccione Childhood Cancer Research Program, BC Children's Hospital Research Institute, Vancouver, BC, Canada.
Jenna Rever *Michael Cuccione Childhood Cancer Research Program, BC Children's Hospital Research Institute, Vancouver, BC, Canada.ORCID 0000-0001-8889-2063
Mario FidanzaMichael Cuccione Childhood Cancer Research Program, BC Children's Hospital Research Institute, Vancouver, BC, Canada.
Wendy DueyDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Samuel SalitraMichael Cuccione Childhood Cancer Research Program, BC Children's Hospital Research Institute, Vancouver, BC, Canada.ORCID 0000-0003-3389-228X
Junia MyungMichael Cuccione Childhood Cancer Research Program, BC Children's Hospital Research Institute, Vancouver, BC, Canada.
Meiyun GuoMichael Cuccione Childhood Cancer Research Program, BC Children's Hospital Research Institute, Vancouver, BC, Canada.
Sumin JoMichael Cuccione Childhood Cancer Research Program, BC Children's Hospital Research Institute, Vancouver, BC, Canada.ORCID 0000-0003-1445-9392
Anuli UzozieMichael Cuccione Childhood Cancer Research Program, BC Children's Hospital Research Institute, Vancouver, BC, Canada.
Fatemeh BaharvandMichael Cuccione Childhood Cancer Research Program, BC Children's Hospital Research Institute, Vancouver, BC, Canada.ORCID 0000-0002-2492-1061
Nina RolfMichael Cuccione Childhood Cancer Research Program, BC Children's Hospital Research Institute, Vancouver, BC, Canada.ORCID 0000-0002-4531-2994
Franziska AuerDepartment of Pediatrics, Children's Cancer Research Center, Kinderklinik München Schwabing, School of Medicine, Technical University of Munich, Munich, Germany.ORCID 0000-0002-1193-6002
Julia HauerDepartment of Pediatrics, Children's Cancer Research Center, Kinderklinik München Schwabing, School of Medicine, Technical University of Munich, Munich, Germany.
Stephan A GruppAbramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0001-8030-7595
Patrice EydouxDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Philipp F LangeMichael Cuccione Childhood Cancer Research Program, BC Children's Hospital Research Institute, Vancouver, BC, Canada.ORCID 0000-0003-1171-5864
Alix E SeifAbramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-1799-2582
Christopher A MaxwellMichael Cuccione Childhood Cancer Research Program, BC Children's Hospital Research Institute, Vancouver, BC, Canada.ORCID 0000-0002-0713-7136
Gregor S D ReidMichael Cuccione Childhood Cancer Research Program, BC Children's Hospital Research Institute, Vancouver, BC, Canada. gregor.reid@ubc.ca.ORCID 0000-0002-7567-3424
BC Children's Hospital · CAUniversity of British Columbia · CACancer Research Institute · USMünchen Klinik Schwabing · DEUniversity of British Columbia Hospital · CA

Funding

Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre (Skin Research Training Centre) MOP-126122
6 · The paper itself

Abstract

The presence of supernumerary chromosomes is the only abnormality shared by all patients diagnosed with high-hyperdiploid B cell acute lymphoblastic leukemia (HD-ALL). Despite being the most frequently diagnosed pediatric leukemia, the lack of clonal molecular lesions and complete absence of appropriate experimental models have impeded the elucidation of HD-ALL leukemogenesis. Here, we report that for 23 leukemia samples isolated from moribund Eμ-Ret mice, all were characterized by non-random chromosomal gains, involving combinations of trisomy 9, 12, 14, 15, and 17. With a median gain of three chromosomes, leukemia emerged after a prolonged latency from a preleukemic B cell precursor cell population displaying more diverse aneuploidy. Transition from preleukemia to overt disease in Eμ-Ret mice is associated with acquisition of heterogeneous genomic abnormalities affecting the expression of genes implicated in pediatric B-ALL. The development of abnormal centrosomes in parallel with aneuploidy renders both preleukemic and leukemic cells sensitive to inhibitors of centrosome clustering, enabling targeted in vivo depletion of leukemia-propagating cells. This study reveals the Eμ-Ret mouse to be a novel tool for investigating HD-ALL leukemogenesis, including supervision and selection of preleukemic aneuploid clones by the immune system and identification of vulnerabilities that could be targeted to prevent relapse.

Indexed as

Disease Models, AnimalPrecursor B-Cell Lymphoblastic Leukemia-LymphomaAneuploidyAnimalsCentrosomeDiploidyHumansMicePrecursor Cell Lymphoblastic Leukemia-Lymphoma

Identifiers

PMID38519798
PMCPMC11073968
OpenAlexW4393097001

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.